
Open Pharma update: January - March 2020

Open Pharma had a great start to 2020, welcoming two new Supporters – Alexion and Novartis! On 21 January, our new and existing Members and Supporters met, alongside other stakeholders in academic publishing, for a roundtable meeting, which was kindly hosted by GSK at GSK House in Brentford, UK. The full meeting report is available on the Open Pharma blog and figshare page!

January was a busy month for Open Pharma as we also presented one poster titled 'How open are pharma publications?' and one poster communication titled 'Registration and use of ORCID by pharma' at the 2020 European Meeting of ISMPP. Both posters are also available to download from the Open Pharma blog and figshare.

Since its launch in October 2019, the Open Pharma position statement on open access has gained 100 individual endorsements from 17 countries! The number of company endorsements of the position statement is also growing, following the recent endorsement from pharma company Ipsen and publishers MDPI and PLOS. If you haven't already, you can read and endorse the position statement on the Open Pharma blog.



Coming up

The Open Pharma virtual roundtable meeting will take place in June 2020. Topics for discussion include ORCID, transformative agreements and how to improve the visibility of publications.

Oxford PharmaGenesis takes part in a number of activities revolving around open science to help Open Pharma gather insight and build a strong network of supporters; these activities go beyond the core Open Pharma plan and are carried out at no cost to Open Pharma.